These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

849 related items for PubMed ID: 26165806

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.
    Bottoni G, Piccardo A, Fiz F, Siri G, Matteucci F, Rocca A, Nanni O, Monti M, Brain E, Alberini JL, Dib B, Sacchetti GM, Saggia C, Rossi V, Harbeck N, Wuerstlein R, Degenhardt T, DeCensi A, Rollandi GA, Gennari A.
    Eur J Radiol; 2021 Aug; 141():109821. PubMed ID: 34139575
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
    Iagaru A, Young P, Mittra E, Dick DW, Herfkens R, Gambhir SS.
    Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL, Xue YL, Song HJ, Luo QY.
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of 18F-FDG positron emission tomography/computed tomography and computed tomography in patients with already-treated breast cancer: diagnostic and prognostic implications.
    Evangelista L, Baretta Z, Vinante L, Bezzon E, De Carolis V, Cervino AR, Gregianin M, Ghiotto C, Saladini G, Pomerri F, Muzzio PC.
    Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):375-84. PubMed ID: 23013667
    [Abstract] [Full Text] [Related]

  • 11. Prospective Study of Serial 18F-FDG PET and 18F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer.
    Peterson LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, Jenkins I, Lee JH, Shields A, Montgomery S, Linden HM, Gralow J, Gadi VK, Muzi M, Kinahan P, Mankoff D, Specht JM.
    J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience.
    Teke F, Teke M, Inal A, Kaplan MA, Kucukoner M, Aksu R, Urakci Z, Tasdemir B, Isikdogan A.
    Asian Pac J Cancer Prev; 2015 Dec; 16(1):387-91. PubMed ID: 25640386
    [Abstract] [Full Text] [Related]

  • 16. The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
    Cochet A, David S, Moodie K, Drummond E, Dutu G, MacManus M, Chua B, Hicks RJ.
    Cancer Imaging; 2014 Apr 22; 14(1):13. PubMed ID: 25608599
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 18F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer.
    Brito AE, Santos A, Sasse AD, Cabello C, Oliveira P, Mosci C, Souza T, Amorim B, Lima M, Ramos CD, Etchebehere E.
    Oncotarget; 2017 May 30; 8(22):36001-36011. PubMed ID: 28415595
    [Abstract] [Full Text] [Related]

  • 20. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.
    Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC.
    Cancer; 2015 Nov 15; 121(22):3965-74. PubMed ID: 26249241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.